theranostics
The firm presented early data for a blood-based approach to screen prostate cancer patients for PSMA, which it believes has advantages over PET imaging.
Telix Pharmaceuticals to License FAP-Targeting Radiopharmaceuticals From German Researchers
The firm is paying €7 million to add fibroblast activation protein-targeting assets to its pipeline, which it will initially develop for bladder cancer.
Alpha-9 Oncology Raises $175M in Series C Financing
The firm will use the funds to advance its pipeline of radiopharmaceutical agents, including an imaging agent currently being studied in melanoma.
Akiram Therapeutics' CD44v6-Targeted Radiopharmaceutical to Enter Phase I Trials in Sweden
Swedish regulators cleared a clinical trial application, allowing Karolinska University Hospital investigators to begin studying 177Lu-AKIR001.
GE HealthCare, University Medicine Essen Partner to Advance Theranostics
GE HealthCare will equip a new Theranostics Center of Excellence in Germany with advanced PET/CT imaging and artificial intelligence technologies.